Influenza Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Influenza Vaccine Market By Vaccine Type (Killed or Inactivated Vaccine, Live Vaccine), By Strain Type (Trivalent Influenza Vaccine, Quadrivaleant Influenza Vaccine), By Formulation Type (Injections, Nasal Sprays), By Distribution Channel (Government Immunization programmes, Non Governmental Organizations (NGOs), Hospitals, Clinics) and Geography 

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Influenza Vaccine Market size was estimated at USD 5206.73 Mn in 2021, growing at a CAGR of 8.3% during the forecast period 2022-2028. Influenza is commonly known as “flu” or “seasonal flu” caused by influenza virus. The symptoms of influenza can be mild to severe ranging from fever to pneumonia. Influenza mainly affected by three type’s influenza virus, called type A, type B and type C. Influenza virus generally spread through the air by coughing and sneezing or touching contaminated surfaces by a virus. Influenza can be diagnosed by testing throat, sputum and nose. Numbers of rapid tests are available for detecting influenza virus. Influenza can be treated with antiviral drugs or prevented by administering influenza vaccine and several other fluid management methods. Influenza virus spreads around the world in yearly outbreaks that result in millions of severe illness and thousands of deaths across the world. WHO every year predicts few strains which are expected to circulate in following year, that allows pharmaceutical companies to develop influenza vaccine against these stains. Recommendation by WHO and U.S’s Centers for Disease Control and Prevention (CDC) for yearly vaccination in high-risk group patients, cost of effectiveness of seasonal influenza vaccine in different age groups and settings expected to drive the market for influenza vaccine over the forecast period. Moreover reduced healthcare burden due to influenza vaccination expected to propel the market for influenza vaccine. For instance, in 2015-2016 influenza seasons, CDC estimates that influenza vaccination prevented approximately 5.1 million influenza illnesses, 2.5 million influenza-associated medical visits, and 71,000 influenza-associated hospitalizations. However, Influenza vaccine made in a year may not be effective in following year owing to evolving nature of influenza virus, in healthy individual influenza vaccine is modestly effective, sometimes new strain or overlooked strain become prevalent in that season, and product recalls which may hamper the uptake and growth.


Influenza Vaccine Market

MARKET SUMMARY
-
8.3% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 8.3%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Influenza Vaccine Market

  • The report on global Influenza Vaccine Market gives historical, current, and future market sizes (US$ Mn) on the basis of vaccine type, strain type, formulation type, end user, and regiony
  • global Influenza Vaccine Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • In Jan 2016, CSL Limited acquired Novartis AG’s influenza vaccine business in Germany, as a part of global influenza vaccine
  • In June 2016, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has recommended not to use AstraZeneca’s FluMist Quadrivalent Influenza vaccine in any settings owing to lack of statistically significant effectiveness in children
Market Key Players
  • GlaxoSmithKline plc.
  • Seqirus (CSL Limited)
  • AstraZeneca
  • Sanofi Pasteur Inc.
  • Sinovac Biotech Ltd.
  • Novavax, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Mitsubishi Tanabe Pharma.
Drivers And Restraints

Influenza Vaccine Market

Players in influenza vaccines market focusing on developing effective vaccine i.e.quadrivalent against influenza virus and eyeing on expanding geographic presence to increase the market revenue for influenza vaccine products. For Instance, in June 2016, Sanofi received a positive end of a procedure from the German which helps in getting market authorization for VaxigripTetra, a quadrivalent vaccine against influenza. Several leading players in influenza vaccine market shipping the vaccine to U.S. market to meet seasonal demand in the country. Securing government tenders has become essential for influenza vaccine manufacturers to gain larger market share and helps in sustaining the business. For instance, in 2015, Sinovac Biotech Ltd. received the tender award from Beijing government to supply seasonal influenza vaccine.


North-America got significant share

Influenza Vaccine Market

Influenza Vaccines market has been segmented into five regions Viz. North Americas, Europe, Asia Pacific, Latin America and the Middle East and Africa. Each year, there are two seasons of influenza because of northern and southern hemispheres have winter in different times. An occurrence of influenza infections high in developing countries than developed counters which make the market lucrative for players in developing countries. However in North America expected to witness significant growth owing U.S.’s yearly vaccination programme. In Europe influenza vaccine limited to the high-risk groups rather than blanket vaccination programmes which market to grow at moderate growth rate. Asia Pacific market expected to grow at significant CAGR owing to increasing affordability, larger and subsidized immunization programs in several countries in the Asia region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, and forecast from 2021-2027
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Segmentation

Influenza Vaccine Market


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • GlaxoSmithKline plc.
  • Seqirus (CSL Limited)
  • AstraZeneca
  • Sanofi Pasteur Inc.
  • Sinovac Biotech Ltd.
  • Novavax, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Mitsubishi Tanabe Pharma.
  • Protein Sciences Corporation

Description

Influenza Vaccine Market size was estimated at USD 5206.73 Mn in 2021, growing at a CAGR of 8.3% during the forecast period 2022-2028. Influenza is commonly known as “flu” or “seasonal flu” caused by influenza virus. The symptoms of influenza can be mild to severe ranging from fever to pneumonia. Influenza mainly affected by three type’s influenza virus, called type A, type B and type C. Influenza virus generally spread through the air by coughing and sneezing or touching contaminated surfaces by a virus. Influenza can be diagnosed by testing throat, sputum and nose. Numbers of rapid tests are available for detecting influenza virus. Influenza can be treated with antiviral drugs or prevented by administering influenza vaccine and several other fluid management methods. Influenza virus spreads around the world in yearly outbreaks that result in millions of severe illness and thousands of deaths across the world. WHO every year predicts few strains which are expected to circulate in following year, that allows pharmaceutical companies to develop influenza vaccine against these stains. Recommendation by WHO and U.S’s Centers for Disease Control and Prevention (CDC) for yearly vaccination in high-risk group patients, cost of effectiveness of seasonal influenza vaccine in different age groups and settings expected to drive the market for influenza vaccine over the forecast period. Moreover reduced healthcare burden due to influenza vaccination expected to propel the market for influenza vaccine. For instance, in 2015-2016 influenza seasons, CDC estimates that influenza vaccination prevented approximately 5.1 million influenza illnesses, 2.5 million influenza-associated medical visits, and 71,000 influenza-associated hospitalizations. However, Influenza vaccine made in a year may not be effective in following year owing to evolving nature of influenza virus, in healthy individual influenza vaccine is modestly effective, sometimes new strain or overlooked strain become prevalent in that season, and product recalls which may hamper the uptake and growth.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX